Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients

S. Matthijs Boekholdt, Benoit J. Arsenault, G. Kees Hovingh, Samia Mora, Terje R. Pedersen, John C. LaRosa, K. M. A. Welch, Pierre Amarenco, David A. DeMicco, Andrew M. Tonkin, David R. Sullivan, Adrienne Kirby, Helen M. Colhoun, Graham A. Hitman, D. John Betteridge, Paul N. Durrington, Michael B. Clearfield, John R. Downs, Antonio M. Gotto, Paul M. RidkerJohn J. P. Kastelein

Research output: Contribution to journalArticlepeer-review

Abstract

It is unclear whether levels of high-density lipoprotein cholesterol (HDL-C) or apolipoprotein A-I (apoA-I) remain inversely associated with cardiovascular risk among patients who achieve very low levels of low-density lipoprotein cholesterol on statin therapy. It is also unknown whether a rise in HDL-C or apoA-I after initiation of statin therapy is associated with a reduced cardiovascular risk.
Original languageEnglish
Pages (from-to)1504-1512
Number of pages9
JournalCirculation
Volume128
Issue number14
DOIs
Publication statusPublished - 2013

Fingerprint

Dive into the research topics of 'Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients'. Together they form a unique fingerprint.

Cite this